Madrigal Pharmaceuticals (MDGL)
(Delayed Data from NSDQ)
$252.74 USD
+4.06 (1.63%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $253.00 +0.26 (0.10%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Madrigal (MDGL) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$350.79 | $411.00 | $150.00 | 41.06% |
Price Target
Based on short-term price targets offered by 14 analysts, the average price target for Madrigal comes to $350.79. The forecasts range from a low of $150.00 to a high of $411.00. The average price target represents an increase of 41.06% from the last closing price of $248.68.
Analyst Price Targets (14)
Broker Rating
Madrigal currently has an average brokerage recommendation (ABR) of 1.53 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 17 brokerage firms. The current ABR compares to an ABR of 1.53 a month ago based on 17 recommendations.
Of the 17 recommendations deriving the current ABR, 13 are Strong Buy, representing 76.47% of all recommendations. A month ago, Strong Buy represented 76.47%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/MDGL.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 13 | 13 | 13 | 13 | 12 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 3 | 3 | 3 | 3 | 2 |
Sell | 1 | 1 | 1 | 1 | 1 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.53 | 1.53 | 1.53 | 1.53 | 1.47 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/8/2024 | H.C. Wainwright & Co. | Ed Arce | Strong Buy | Strong Buy |
8/8/2024 | Evercore Partners | Liisa A Bayko | Strong Buy | Strong Buy |
8/8/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
8/7/2024 | SVB Securities | Thomas J Smith | Strong Buy | Strong Buy |
8/7/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
8/7/2024 | Not Identified | Not Identified | Hold | Hold |
7/16/2024 | JMP Securities | Jonathan Wolleben | Strong Buy | Strong Buy |
7/2/2024 | Piper Sandler | Yasmeen Rahimi | Strong Buy | Strong Buy |
6/28/2024 | Cantor Fitzgerald & Co | Prakhar Agrawal | Not Available | Hold |
6/11/2024 | Not Identified | Not Identified | Not Available | Strong Buy |
4/1/2024 | Cowen & Co. | Ritu S Baral | Strong Buy | Strong Buy |
3/15/2024 | UBS | Eliana Merle | Strong Buy | Strong Buy |
3/15/2024 | B. Riley Securities | Mayank Mamtani | Strong Sell | Hold |
3/8/2024 | Canaccord Genuity | Edward H Nash | Strong Buy | Strong Buy |
12/1/2023 | Goldman Sachs | Andrea Tan | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.53 |
ABR (Last week) | 1.53 |
# of Recs in ABR | 17 |
Average Target Price | $350.79 |
LT Growth Rate | NA |
Industry | Medical - Drugs |
Industry Rank by ABR | 96 of 253 |
Current Quarter EPS Est: | -7.58 |